Changes and Inequities in Adult Mental Health-Related Emergency Department Visits During the COVID-19 Pandemic in the US.
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
17
3
2022
medline:
7
5
2022
entrez:
16
3
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has negatively affected adult mental health (MH), with racial and ethnic minoritized groups disproportionately affected. To examine changes in adult MH-related emergency department (ED) visits into the Delta variant pandemic period and identify changes and inequities in these visits before and during COVID-19 case surges. This epidemiologic cross-sectional study used National Syndromic Surveillance Program data from US adults aged 18 to 64 years from 1970 to 2352 ED facilities from January 1, 2019, to August 14, 2021. All MH-related ED visits and visits related to 10 disorders (ie, anxiety, depressive, bipolar, schizophrenia spectrum, trauma- and stressor-related, attention-deficit/hyperactivity, disruptive behavioral and impulse, obsessive-compulsive, eating, and tic disorders) were identified. The following periods of MH-related ED visits were compared: (1) high Delta variant circulation (July 18-August 14, 2021) with a pre-Delta period (April 18-May 15, 2021), (2) after a COVID-19 case peak (February 14-March 13, 2021) with during a peak (December 27, 2020-January 23, 2021), and (3) the Delta period and the period after a COVID-19 case peak with the respective corresponding weeks during the prepandemic period. ED visits for 10 mental disorders and all MH-related visits. This cross-sectional study included 107 761 319 ED visits among adults aged 18 to 64 years (59 870 475 [56%] women) from January 1, 2019, to August 14, 2021. There was stability in most MH-related ED visit counts between the Delta and pre-Delta periods (percentage change, -1.4% to -7.5%), except for eating disorders (-11.9%) and tic disorders (-19.8%) and after a COVID-19 case peak compared with during a peak (0.6%-7.4%). Most MH-related ED visit counts declined in the Delta period relative to the prepandemic period (-6.4% to -30.7%); there were fluctuations by disorder when comparing after a COVID-19 case peak with the corresponding prepandemic period (-15.4% to 11.3%). Accounting for ED visit volume, MH-related ED visits were a smaller proportion of visits in the Delta period compared with the pre-Delta period (visit ratio, 0.86; 95% CI, 0.85-0.86) and prepandemic period (visit ratio, 0.80; 95% CI, 0.79-0.80). After a COVID-19 case peak, MH-related ED visits were a larger proportion of ED visits compared with during a peak (visit ratio, 1.04; 95% CI, 1.03-1.04) and the corresponding prepandemic period (visit ratio, 1.11; 95% CI, 1.11-1.12). Of the 2 510 744 ED visits included in the race and ethnicity analysis, 24 592 (1%) were American Indian or Alaska Native persons, 33 697 (1%) were Asian persons, 494 198 (20%) were Black persons, 389 740 (16%) were Hispanic persons, 5000 (0.2%) were Native Hawaiian or Other Pacific Islander persons, and 1 172 683 (47%) were White persons. There was between- and within-group variation in ED visits by race and ethnicity and increases in selected disorders after COVID-19 peaks for adults aged 18 to 24 years. Results of this cross-sectional study suggest that EDs may have increases in MH-related visits after COVID-19 surges, specifically for young adults and individual racial and ethnic minoritized subpopulations. Public health practitioners should consider subpopulation-specific messaging and programmatic strategies that address differences in MH needs, particularly for those historically marginalized.
Identifiants
pubmed: 35293958
pii: 2790337
doi: 10.1001/jamapsychiatry.2022.0164
pmc: PMC8928092
mid: NIHMS1790190
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-485Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Références
JAMA Netw Open. 2019 Dec 2;2(12):e1917550
pubmed: 31834397
Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):223-234
pubmed: 33025099
JAMA Psychiatry. 2021 Apr 1;78(4):372-379
pubmed: 33533876
J Gen Intern Med. 2022 Jan;37(1):49-56
pubmed: 33821410
J Health Polit Policy Law. 2020 Dec 1;45(6):937-950
pubmed: 32464657
Front Med (Lausanne). 2020 Jun 25;7:300
pubmed: 32671081
Pediatrics. 2020 Nov;146(5):
pubmed: 32873719
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):699-704
pubmed: 32525856
Psychother Psychosom. 2021;90(1):64-66
pubmed: 32498070
JAMA Netw Open. 2021 Feb 1;4(2):e2037665
pubmed: 33606030
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):490-494
pubmed: 33793459
MMWR Morb Mortal Wkly Rep. 2021 Feb 05;70(5):162-166
pubmed: 33539336
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Perspect Psychol Sci. 2022 Jul;17(4):915-936
pubmed: 35044275
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
JAMA Intern Med. 2021 Mar 1;181(3):388-391
pubmed: 33196765
West J Emerg Med. 2012 Nov;13(5):410-5
pubmed: 23359637
Depress Anxiety. 2011 Aug;28(8):648-57
pubmed: 21796740
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057
pubmed: 32790653
Health Aff (Millwood). 2021 Feb;40(2):349-358
pubmed: 33523745
Ann Intern Med. 2021 Mar;174(3):428-430
pubmed: 33197214
MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):552-556
pubmed: 33857069
Mov Disord Clin Pract. 2020 Jul 03;7(6):725-726
pubmed: 32775530
BMJ Glob Health. 2018 Mar 17;3(2):e000471
pubmed: 29607096
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-1521
pubmed: 33090984
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33875593
Psychol Med. 2021 Jan;51(2):201-211
pubmed: 33436130
Front Pediatr. 2019 Dec 19;7:525
pubmed: 31956644
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):382-388
pubmed: 33735165
MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):566-569
pubmed: 33857062